74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Lexicon Pharmaceuticals Inc
Closed
SectorHealthcare
0.7 6.06
Overview
Share price change
24h
Min
0.65
Max
0.75
Income | 31M -34M |
|---|---|
Sales | 25M 27M |
EPS | -0.09 |
Profit margin | -127.16 |
Employees | 103 |
EBITDA | 30M -30M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +646.27% upside |
Next Earnings | 1 May 2025 |
|---|
Market Cap | 102M 208M |
|---|---|
Previous open | -5.36 |
Previous close | 0.7 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Lexicon Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Lexicon Pharmaceuticals Inc Forecast
Price Target
By TipRanks
646.27% upside
12 Months Forecast
Average 5 USD 646.27%
High 6 USD
Low 4 USD
Based on 3 Wall Street analysts offering 12 month price targets forLexicon Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
